Chicago-based Tempus, which uses AI for drug discovery, clinical trials, and diagnostics, raised $275M in equity and debt, bringing its total funding to $1.3B+
This is not your average raise. — Biotech upstart Tempus announced on Thursday it raised $275 million through equity …
Context & Ripple Effects
The October 2022 round was the last big private step before Tempus went public: the company later filed for an IPO disclosing a $266M net loss on $532M revenue in 2023, then priced at $37 a share to raise $410.7M at a $6.1B valuation. This $275M in equity and debt pushed cumulative funding past $1.3B, which is what carried the money-losing diagnostics business to listing day.
The mixed structure matters: debt alongside equity signals lenders were willing to underwrite an AI healthcare company still burning cash, roughly twenty months before its Nasdaq debut closed up 8.8% at $40.25.
First-order effects
- Tempus gains fresh capital for its three-pronged model — AI drug discovery, clinical trial matching, and diagnostics — without immediately diluting existing holders via an all-equity deal.
- Debt investors join the cap table's risk profile, effectively betting that Tempus's recurring diagnostics revenue can service borrowings ahead of any exit.
Second-order effects
- A $1.3B+ war chest lets Tempus outspend smaller AI-diagnostics rivals on data partnerships and lab capacity, pressuring competitors to raise on similar terms or sell.
- For Chicago's startup scene, Tempus becomes the local proof case that a deep-tech company can assemble billion-dollar private stacks outside the coastal hubs — a narrative the city has since leaned into with its quantum computing campus plans.
Third-order effects
- If the pattern holds — massive private rounds bridging loss-making AI healthcare companies to public listings, as Tempus's path from this raise to its $6.6B debut shows — public-market investors become the ultimate funders of AI medicine's data buildout, with losses tolerated far longer than traditional biotech norms allowed.
The trend: AI healthcare companies are using ever-larger hybrid private rounds as bridge financing toward public listings that absorb their continued losses.